Physician profile
Robert E Chalmers
NPI 1760911879
$4,068.75
in general payments reported to CMS, 2019-2025
33 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $200 · 2021: $1,341 · 2022: $1,016 · 2023: $638 · 2024: $470 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456 · Education: $56.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.94 |
| Education | $56.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $692.50 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $636.46 | 2020-2025 | Vraylar, Ubrelvy, Viberzi |
| Glaxosmithkline, LLC. | $486.85 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Pfizer INC. | $449.77 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.59 | 2020-2025 | Jardiance, Ofev |
| Amgen INC. | $178.02 | 2021-2024 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $130.80 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $116.88 | 2021-2023 | Gvoke Hypopen |
| Lilly USA, LLC | $111.00 | 2021-2022 | |
| Abbott Laboratories | $110.95 | 2021-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $88.93 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $71.10 | 2021 | |
| Sunovion Pharmaceuticals INC. | $70.45 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.04 | 2021-2022 | |
| Medtronic, INC. | $53.86 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $49.36 | 2020-2025 | Airsupra |
| Novartis Pharmaceuticals Corporation | $41.72 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.88 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $35.59 | 2022 | |
| Genentech USA, INC. | $35.03 | 2020 | |
| Dexcom, INC. | $33.60 | 2021-2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $32.54 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $27.80 | 2024-2025 | Veozah |
| Eisai INC. | $25.09 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $23.93 | 2023 | Rexulti |
| Ultragenyx Pharmaceutical INC. | $20.38 | 2021 | |
| Silk Road Medical, INC. | $20.13 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Esperion Therapeutics, INC. | $18.11 | 2021 | |
| Nevro Corp. | $17.94 | 2022 | |
| Daiichi Sankyo INC. | $17.58 | 2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $17.57 | 2023 | Eliquis |
| Kyowa Kirin, INC. | $13.50 | 2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chalmers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.